Biomarkers must show clinical utility by improving patient outcomes before they can be used in regular clinical practice; this includes leading to actions that positively impact patients.
Conducting randomized trials for early detection of diseases is expensive and time-consuming, requiring special design considerations.
The commentary outlines recommendations for biomarker-driven studies, discussing study features, endpoints, performance criteria, and innovative methods like real-world evidence and mathematical modeling to enhance trial efficiency.